Epizyme Gets a Buy Rating from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Epizyme (NASDAQ: EPZM) today and set a price target of $25. The company’s shares opened today at $12.95.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.7% and a 45.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $23, representing a 77.6% upside.

In a report issued on June 5, Oppenheimer also reiterated a Buy rating on the stock with a $26 price target.

Based on Epizyme’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $32.52 million. In comparison, last year the company earned revenue of $472K and had a GAAP net loss of $22.88 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Epizyme, Inc. operates as a clinical stage biopharmaceutical company. The company discovers, develops and plans to commercialize therapeutics for patients with genetically defined cancers. It engages in the creation of small molecule inhibitors of class of enzymes known as histone methyltransferases. The company products include Tazemetostat, which is used for the treatment of multiple types of hematological malignancies and genetically defined solid tumors; and Pinometostat, which is used for treatment of patients with MLL-r, a genetically defined acute leukemia. Epizyme was founded by H. Robert Horvitz and Yi Zhang on November 1, 2007 and is headquartered in Cambridge, MA.